New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab

Seminars in Thrombosis and Hemostasis

Volumn 36, Issue 6, 2010, Pages 669-672

  Köse, Özlem ^a   Zimmerhackl, Lothar Bernd ^b   Jungraithmayr, Therese ^b   MacHe, Christoph ^c   Nürnberger, Jens ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Atypical hemolytic uremic syndrome; complement activation; complement inhibitor; eculizumab

Indexed keywords

ECULIZUMAB;

ACUTE KIDNEY FAILURE; ARTHRALGIA; BACKACHE; BLOOD TRANSFUSION; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG MANUFACTURE; DRUG MECHANISM; DRUG SAFETY; FEVER; GASTROINTESTINAL INFECTION; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; INTRAVASCULAR HEMOLYSIS; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NAUSEA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOGENESIS; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REPEATED DRUG DOSE; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SHORT SURVEY; SINGLE DRUG DOSE; THROMBOCYTOPENIA; THROMBOSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT INDICATION; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; COMPLEMENT C3B INACTIVATOR PROTEINS; COMPLEMENT C5; COMPLEMENT FACTOR H; COMPLEMENT PATHWAY, ALTERNATIVE; FEMALE; GENE DELETION; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MUTATION; POLYMORPHISM, GENETIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77957602105     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1262889     Document Type: Short Survey

References (14)

1. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009 361 (17) 1676-1687
2. Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005 16 (4) 1035-1050
3. Jokiranta T S., Zipfel P F., Frmeaux-Bacchi V, Taylor C M., Goodship T J., Noris M. Where next with atypical hemolytic uremic syndrome? Mol Immunol 2007 44 (16) 3889-3900
4. Atkinson J P., Goodship T H. Complement factor H and the hemolytic uremic syndrome. J Exp Med 2007 204 (6) 1245-1248
5. Loirat C, Noris M, Frmeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2008 23 (11) 1957-1972
6. Thomas T C., Rollins S A., Rother R P. et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 1996 33 (17-18) 1389-1401
7. Hillmen P, Hall C, Marsh J C. et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004 350 (6) 552-559
8. Hillmen P, Young N S., Schubert J et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006 355 (12) 1233-1243
9. Shin J I., Lee J S. More on eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009 360 (20) 2142-2143; author reply 2143
10. Nürnberger J, Philipp T, Witzke O et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009 360 (5) 542-544
11. Gruppo R A., Rother R P. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009 360 (5) 544-546
12. Mache C J., Acham-Roschitz B, Frmeaux-Bacchi V et al. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009 4 (8) 1312-1316
13. Chatelet V, Frmeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de Ligny B. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 2009 9 (11) 2644-2645
14. Davin J C., Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis 2010 55 (4) 708-711